CO5080734A1 - Compuestos amino que poseen actividad neuronal - Google Patents
Compuestos amino que poseen actividad neuronalInfo
- Publication number
- CO5080734A1 CO5080734A1 CO98048806D CO98048806D CO5080734A1 CO 5080734 A1 CO5080734 A1 CO 5080734A1 CO 98048806 D CO98048806 D CO 98048806D CO 98048806 D CO98048806 D CO 98048806D CO 5080734 A1 CO5080734 A1 CO 5080734A1
- Authority
- CO
- Colombia
- Prior art keywords
- straight
- branched
- alkenyl
- alkyl
- alkynyl
- Prior art date
Links
- -1 AMINO COMPOUNDS Chemical class 0.000 title abstract 14
- 230000001537 neural effect Effects 0.000 title 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 18
- 125000003342 alkenyl group Chemical group 0.000 abstract 13
- 125000000304 alkynyl group Chemical group 0.000 abstract 12
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 9
- 125000000217 alkyl group Chemical group 0.000 abstract 8
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 abstract 7
- 229910052760 oxygen Inorganic materials 0.000 abstract 7
- 229910052717 sulfur Inorganic materials 0.000 abstract 7
- 229910052757 nitrogen Inorganic materials 0.000 abstract 6
- 229910052739 hydrogen Inorganic materials 0.000 abstract 5
- 239000001257 hydrogen Substances 0.000 abstract 5
- 125000006729 (C2-C5) alkenyl group Chemical group 0.000 abstract 4
- 150000002431 hydrogen Chemical group 0.000 abstract 4
- 229910052799 carbon Inorganic materials 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- 125000006709 (C5-C7) cycloalkenyl group Chemical group 0.000 abstract 2
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 abstract 2
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 abstract 2
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 abstract 2
- 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 abstract 2
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 abstract 2
- 125000005002 aryl methyl group Chemical group 0.000 abstract 2
- 125000005605 benzo group Chemical group 0.000 abstract 2
- 150000003857 carboxamides Chemical class 0.000 abstract 2
- 125000000392 cycloalkenyl group Chemical group 0.000 abstract 2
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 2
- 125000004210 cyclohexylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 abstract 2
- 125000000714 pyrimidinyl group Chemical group 0.000 abstract 2
- 229940124530 sulfonamide Drugs 0.000 abstract 2
- 150000003456 sulfonamides Chemical class 0.000 abstract 2
- 125000000335 thiazolyl group Chemical group 0.000 abstract 2
- 125000006705 (C5-C7) cycloalkyl group Chemical group 0.000 abstract 1
- 125000004605 1,2,3,4-tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 abstract 1
- 125000004607 1,2,3,4-tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 abstract 1
- 125000004502 1,2,3-oxadiazolyl group Chemical group 0.000 abstract 1
- 125000001399 1,2,3-triazolyl group Chemical group N1N=NC(=C1)* 0.000 abstract 1
- 125000004504 1,2,4-oxadiazolyl group Chemical group 0.000 abstract 1
- 125000004514 1,2,4-thiadiazolyl group Chemical group 0.000 abstract 1
- 125000001376 1,2,4-triazolyl group Chemical group N1N=C(N=C1)* 0.000 abstract 1
- 125000004520 1,3,4-thiadiazolyl group Chemical group 0.000 abstract 1
- 125000003363 1,3,5-triazinyl group Chemical group N1=C(N=CN=C1)* 0.000 abstract 1
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 abstract 1
- 125000005955 1H-indazolyl group Chemical group 0.000 abstract 1
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 abstract 1
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 abstract 1
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 abstract 1
- 125000003682 3-furyl group Chemical group O1C([H])=C([*])C([H])=C1[H] 0.000 abstract 1
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 229910006069 SO3H Inorganic materials 0.000 abstract 1
- 125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 abstract 1
- 125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 abstract 1
- 125000003828 azulenyl group Chemical group 0.000 abstract 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 abstract 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 abstract 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract 1
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 abstract 1
- 125000002619 bicyclic group Chemical group 0.000 abstract 1
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 abstract 1
- 125000004122 cyclic group Chemical group 0.000 abstract 1
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 abstract 1
- 125000002541 furyl group Chemical group 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 125000002883 imidazolyl group Chemical group 0.000 abstract 1
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 abstract 1
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 abstract 1
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 abstract 1
- 125000001041 indolyl group Chemical group 0.000 abstract 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 abstract 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 abstract 1
- 125000001786 isothiazolyl group Chemical group 0.000 abstract 1
- 125000000842 isoxazolyl group Chemical group 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- 125000002950 monocyclic group Chemical group 0.000 abstract 1
- 125000002757 morpholinyl group Chemical group 0.000 abstract 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 125000002971 oxazolyl group Chemical group 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 125000003386 piperidinyl group Chemical group 0.000 abstract 1
- QLNJFJADRCOGBJ-UHFFFAOYSA-N propionamide Chemical compound CCC(N)=O QLNJFJADRCOGBJ-UHFFFAOYSA-N 0.000 abstract 1
- 229940080818 propionamide Drugs 0.000 abstract 1
- 125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 abstract 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 abstract 1
- 125000003373 pyrazinyl group Chemical group 0.000 abstract 1
- 125000003072 pyrazolidinyl group Chemical group 0.000 abstract 1
- 125000005412 pyrazyl group Chemical group 0.000 abstract 1
- 125000000168 pyrrolyl group Chemical group 0.000 abstract 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 abstract 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 abstract 1
- 125000005493 quinolyl group Chemical group 0.000 abstract 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 abstract 1
- 125000006413 ring segment Chemical group 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
- 125000001113 thiadiazolyl group Chemical group 0.000 abstract 1
- 125000001544 thienyl group Chemical group 0.000 abstract 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 abstract 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/40—Acylated substituent nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Hydrogenated Pyridines (AREA)
Abstract
Un compuesto de la fórmula :<EMI FILE="98048806_1" ID="1" IMF=JPEG >Y derivados farmacéuticamente aceptables de éste, en donde:A y B son seleccionados independientemente de hidrógeno, Ar, alquilo (C1-C6) de cadena recta o ramificada, alquenilo o alquinilo (C2 -C6) de cadena recta o ramificada, alquilo (C1-C6) de cadena recta o ramificada sustituido con cicloalquilo (C5-C7), alquenilo o alquinilo (C2-C6) de cadena recta o ramificada sustituido con cicloalquilo (C5-C7), alquilo (C1-C6) de cadena recta o ramificada sustituido con ciclo-alquenilo (C5-C7), alquenilo o alquinilo (C2-C6) de cadena recta o ramificada sustituido con ciclo-alquenilo (C5-C7), alquilo (C1-C6) de cadena recta o ramificada sustituido con Ar, o alquenilo o alquinilo (C2 -C6) de cadena recta o ramificada sustituido con Ar; en donde cualquiera de los grupos CH2 de dichas cadenas alquilo, alquenilo o alquinilo en A o B es reemplazado opcionalmente por O, S, S(O), S(O)2 o N(R); en donde:R es seleccionado de hidrógeno, alquilo (C1-C6 ) de cadena recta o ramificada, o alquenilo o alquinilo (C2-C6 ) de cadena recta o ramificada;Ar es seleccionado de fenilo, 1-naftilo, 2-naftilo, indenilo, azulenilo, fluorenilo, antracenilo, 2-furilo, 3-furilo, 2-tienilo, 3-tienilo, 2-piridilo, 3-piridilo, 4-piridilo, pirrolilo, oxazolilo, tiazolilo, imidazolilo, piraxolilo, 2-pirazolinilo, pirazolidinilo, isoxazolilo, isotiazolilo, 1,2,3-oxadiazolilo, 1,2,3-triazolilo, 1,3,4-tiadiazolilo, 1,2,3-, tiadiazolilo, 1,2,4 triazolilo, 1,2,4-oxadiazolilo, 1,2,4-tiadiazolilo, benzoxazolilo, piridacinilo, , pirimidinilo, piracinilo, 1,3,5-triazinilo, 1,3,5-tritianilo, indolizinilo, indolilo, isoindolilo, 3H-indolilo, indolinilo, benzo (b(furanilo, benzo(b(tiofenilo, 1H-indazolilo, bencimidazolilo, bencitiazolilo, purinilo, 4H-quinolicinilo, quinolinilo, 1,2,3,4-tetrahidro-isoquinolinilo, isoquinolinilo, 1,2,3,4-tetrahidro-quinolinilo, cinolinilo, ftalacinilo, quinazolinilo, quinoxalinilo, 1,8-naftiridinilo, pteridinilo, carbazolilo, acridinilo, fenacinilo, fenotiacinilo o fenoxacinilo u otros sistemas de anillo monocíclico, bicíclico o tricíclico factible químicamente, en donde cada anillo consiste de 5 a 7 átomos de anillo y en donde cada anillo comprende 0 a 3 heteroátomos seleccionados independientemente de N, N( R), O, S, S(O)2 y en donde:Cada Ar es sustituido opcionalmente con uno de tres sustituyentes seleccionados independientemente de halógeno, hidroxilo, nitro, -SO3H, trifluorometilo, trifluorometoxi, alquilo (C1-C6 ) de cadena recta o ramificada, alquenilo (C2-C6) de cadena recta o ramificada, O- (alquilo(C1-C6 ) de cadena recta o ramificada( , O-(alquenilo (C2-C6 ) de cadena recta o ramificada(, O-bencilo, O-fenilo, - 2 -1,2-metilenodioxi, -N(R1) (R2 ), carboxilo, N-(alquilo (C1-C5 ) de cadena recta o ramificada o alquenilo (C2-C5 ) de cadena recta o ramificada) carboxamidas, N,N-di-(alquilo (C1-C5) de cadena recta o ramificada o alquenilo (C2-C5) de cadena recta o ramificada) carboxamidas, N-(alquilo (C1-C5) de cadena recta o ramificada o alquenilo (C2-C5)) sulfonamidas, N,N-di-(alquilo (C1-C5) de cadena recta o ramificada o alquenilo (C2-C5) de cadena recta o ramificada), sulfonamidas, morfolinilo, piperidinilo, O-Z, CH2 -(CH2 )q -Z, O-(CH2 )q -Z, (CH2 )q -Z-O-Z, o CH=CH-Z;en donde R1 y R2 son seleccionados independientemente de alquilo (C1-C5 ) de cadena recta o ramificada, alquenilo o alquinilo (C2-C6 ) de cadena recta o ramificada, hidrógeno o bencilo; o en donde R1 y R2 en conjunto con el átomo de nitrógeno al cual están unidos forman un anillo heterocíclico de 5-7 miembros;Z es seleccionado de 4-metoxifenilo, 2-piridilo, 3-piridilo, 4-piridilo, piracilo, quinolilo, 3,5-dimetilisoxazolilo, isoxazoilo, 2-metiltiazolilo, tiazolilo, 2-tienilo, 3-tienilo, o pirimidilo; yq es N, O o C( R );X es N, O o C(R );donde cuando X es N o C(R ), Y es seleccionado de hidrógeno, Ar, alquilo (C1-C6 ) de cadena recta o ramificada, alquenilo o alquinilo (C2-C6 ) de cadena recta o ramificada, alquilo (C1-C6 ) de cadena recta o ramificada sustituido con ciclo-alquilo (C5 -C7), alquenilo o alquinilo (C2-C6) de cadena recta o ramificada sustituido con cicloalquilo (C5-C7 ), alquilo (C1-C6 ) de cadena recta o ramificada sustituido con ciclo-alquenilo (C5-C7), alquenilo o alquinilo (C2-C6 ) de cadena recta o ramificada sustituido con ciclo - alquenilo (C5-C7 ), alquilo (C1-C6 ) de cadena recta o ramificada sustituido con Ar, alquenilo o alquinilo (C2-C6 ) de cadena recta o ramificada sustituido con Ar ;cuando X es O, Y es un par solo de electrones;K´ es seleccionado de alquilo (C1-C6 ) de cadena recta o ramificada, alquilo (C1-C6 ) de cadena recta o ramificada sustituido con Ar, alquenilo o alquinilo (C2-C6 ) de cadena recta o ramificada, alquenilo o alquinilo (C2-C6 ) de cadena recta o ramificada sustituido con Ar, o ciclohexilmetilo; en donde cualquiera de los grupos CH2 de dichas cadenas alquilo, alquenilo o alquinilo en K' es reemplazado opcionalmente por O, S, S(O), S(O)2 o N ( R) ;n es 0, 1 ó 2 ;J es seleccionado de hidrógeno, alquilo (C1-C6) de cadena recta o ramificada, alquenilo o alquinilo (C2-C6) de cadena recta o ramificada, alquilo (C1-C6) de cadena recta o ramificada sustituido con Ar, alquenilo o alquinilo (C2-C6) de cadena recta o ramificada sustituido con Ar, o ciclohexilmetilo; yD es seleccionado de Ar, alquilo (C1-C6) de cadena recta o ramificada, alquenilo o alquinilo (C2-C6) de cadena recta o ramificada, alquilo (C1-C6) de cadena recta o ramificada sustituido con ciclo-alquilo (C5-C7) , alquenilo o alquinilo (C2-C6) de cadena recta o ramificada sustituido con ciclo-alquilo (C5-C7), alquilo (C1-C6) de cadena recta o ramificada sustituido con ciclo-alquenilo (C5-C7), alquenilo o alquinilo (C2-C6) de cadena recta o ramificada sustituido con ciclo-alquenilo (C5-C7), alquilo (C1-C6) de cadena recta o ramificada sustituido con Ar, o alquenilo o alquinilo (C2-C6) de cadena recta o ramificada sustituido con Ar; en donde cualquiera de los grupos CH2 de dichas cadenas alquilo en D diferente de uno que está unido al S02 en el compuesto, es reemplazado opcionalmente por O, S, SO, S(0)2 o NR; y Donde el compuesto de fórmula (I) no es ácido (S)- (2-(5-(dimetilamino)-1-naftalensulfonamido)-3-fenil)carboxílico, éster de 1-(piridin-4-il)propilo o (S)- (p- toluenesulfonamido)-3- fenil- N-(2-piridin-2-il)metil)propionamida.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US92083897A | 1997-08-29 | 1997-08-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO5080734A1 true CO5080734A1 (es) | 2001-09-25 |
Family
ID=25444494
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO98048806D CO5080734A1 (es) | 1997-08-29 | 1998-08-26 | Compuestos amino que poseen actividad neuronal |
| CO98048806A CO5080732A1 (es) | 1997-08-29 | 1998-08-26 | Compuestos que poseen actividad neuronal |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO98048806A CO5080732A1 (es) | 1997-08-29 | 1998-08-26 | Compuestos que poseen actividad neuronal |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US6268384B1 (es) |
| JP (1) | JP2010100643A (es) |
| KR (1) | KR100859758B1 (es) |
| AR (1) | AR016875A1 (es) |
| CO (2) | CO5080734A1 (es) |
| IL (1) | IL134536A (es) |
| ZA (1) | ZA987478B (es) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU1708099A (en) | 1998-06-03 | 1999-12-20 | Amgen, Inc. | N-linked sulfonamides of n-heterocyclic carboxylic acids or carboxylic acid isosteres |
| AU5912900A (en) * | 1999-07-06 | 2001-01-22 | Vertex Pharmaceuticals Incorporated | Quinuclidine derivatives for treatment of neurological disorders |
| US6399606B1 (en) * | 1999-11-29 | 2002-06-04 | Nippon Kayaku Co., Ltd. | Neuroprotective agents and methods related thereto |
| WO2003055482A1 (en) * | 2001-12-21 | 2003-07-10 | Novo Nordisk A/S | Amide derivatives as gk activators |
| WO2003089771A1 (en) * | 2002-04-17 | 2003-10-30 | Clearwater International, Llc | Optimizing inlet air temperature for gas trubines using heat exchanging fluid comprising alkali metal formate |
| CA2744893A1 (en) * | 2002-06-27 | 2004-01-08 | Novo Nordisk A/S | Aryl carbonyl derivatives as glucokinase activators |
| MXPA06007667A (es) * | 2004-01-06 | 2006-09-01 | Novo Nordisk As | Heteroaril-ureas y su uso como activadores de glucocinasa. |
| US7777042B2 (en) * | 2004-06-29 | 2010-08-17 | Aventis Pharmaceuticals Inc. | N-sulfonylpipecolic acid derivative FKBP binding composition and pharmaceutical use thereof |
| ATE546430T1 (de) | 2004-06-29 | 2012-03-15 | Aventis Pharma Inc | Fkbp bindende zusammensetzung und deren pharmazeutische verwendung |
| ATE547396T1 (de) * | 2005-07-08 | 2012-03-15 | Novo Nordisk As | Dicycloalkylcarbamoyl-harnstoffe als glucokinase- aktivatoren |
| WO2007006760A1 (en) * | 2005-07-08 | 2007-01-18 | Novo Nordisk A/S | Dicycloalkyl urea glucokinase activators |
| EP1904467B1 (en) | 2005-07-14 | 2013-05-01 | Novo Nordisk A/S | Urea glucokinase activators |
| US8138185B2 (en) * | 2007-01-09 | 2012-03-20 | Novo Nordisk A/S | Urea glucokinase activators |
| US8318778B2 (en) * | 2007-01-11 | 2012-11-27 | Novo Nordisk A/S | Urea glucokinase activators |
| WO2012177896A1 (en) | 2011-06-24 | 2012-12-27 | Amgen Inc. | Trpm8 antagonists and their use in treatments |
| JP2014527511A (ja) | 2011-06-24 | 2014-10-16 | アムジエン・インコーポレーテツド | Ｔｒｐｍ８拮抗剤及び治療におけるそれらの使用 |
| US8952009B2 (en) | 2012-08-06 | 2015-02-10 | Amgen Inc. | Chroman derivatives as TRPM8 inhibitors |
| EP3030556B1 (en) | 2013-09-19 | 2019-10-30 | Technische Universität Darmstadt | Selective fkbp51 ligands for treatment of psychiatric disorders |
| EP3183229A4 (en) * | 2014-08-19 | 2018-04-18 | The Regents of the University of California | Apoe4-targeted theraputics that increase sirt1 |
| CN112040945A (zh) | 2018-06-12 | 2020-12-04 | Vtv治疗有限责任公司 | 葡萄糖激酶激活剂与胰岛素或胰岛素类似物组合的治疗用途 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX9202466A (es) | 1991-05-24 | 1994-06-30 | Vertex Pharma | Compuestos inmunosupresores novedosos. |
| NZ314207A (en) | 1992-09-28 | 2000-12-22 | Vertex Pharma | 1-(2-Oxoacetyl)-piperidine-2-carboxylic acid derivatives as multi drug resistant cancer cell sensitizers |
| US5744485A (en) | 1994-03-25 | 1998-04-28 | Vertex Pharmaceuticals Incorporated | Carbamates and ureas as modifiers of multi-drug resistance |
| IL115685A (en) | 1994-11-16 | 2000-08-31 | Vertex Pharma | Amino acid derivatives pharmaceutical compositions containing the same and processes for the preparation thereof |
| US5543423A (en) | 1994-11-16 | 1996-08-06 | Vertex Pharmaceuticals, Incorporated | Amino acid derivatives with improved multi-drug resistance activity |
| US5696135A (en) | 1995-06-07 | 1997-12-09 | Gpi Nil Holdings, Inc. | Inhibitors of rotamase enzyme activity effective at stimulating neuronal growth |
| US5614547A (en) | 1995-06-07 | 1997-03-25 | Guilford Pharmaceuticals Inc. | Small molecule inhibitors of rotamase enzyme |
| US5859031A (en) | 1995-06-07 | 1999-01-12 | Gpi Nil Holdings, Inc. | Small molecule inhibitors of rotamase enzyme activity |
| US5801197A (en) | 1995-10-31 | 1998-09-01 | Gpi Nil Holdings, Inc. | Rotamase enzyme activity inhibitors |
| US5721256A (en) * | 1997-02-12 | 1998-02-24 | Gpi Nil Holdings, Inc. | Method of using neurotrophic sulfonamide compounds |
-
1998
- 1998-05-27 US US09/085,441 patent/US6268384B1/en not_active Expired - Lifetime
- 1998-08-19 ZA ZA987478A patent/ZA987478B/xx unknown
- 1998-08-25 AR ARP980104214A patent/AR016875A1/es unknown
- 1998-08-26 CO CO98048806D patent/CO5080734A1/es unknown
- 1998-08-26 CO CO98048806A patent/CO5080732A1/es unknown
- 1998-08-27 KR KR1020007002055A patent/KR100859758B1/ko not_active IP Right Cessation
-
2000
- 2000-02-14 IL IL134536A patent/IL134536A/en not_active IP Right Cessation
-
2009
- 2009-12-28 JP JP2009298892A patent/JP2010100643A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| CO5080732A1 (es) | 2001-09-25 |
| US6268384B1 (en) | 2001-07-31 |
| ZA987478B (en) | 1999-02-22 |
| KR20010023413A (ko) | 2001-03-26 |
| KR100859758B1 (ko) | 2008-09-24 |
| JP2010100643A (ja) | 2010-05-06 |
| AR016875A1 (es) | 2001-08-01 |
| IL134536A (en) | 2006-08-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO5080734A1 (es) | Compuestos amino que poseen actividad neuronal | |
| CO5080733A1 (es) | Metodos y composiciones para estimular el crecimiento de neuritas | |
| CO4930260A1 (es) | Metodos y composiciones para estimular el crecimiento de neuritas | |
| CO4920219A1 (es) | Metodos y composiciones para estimular el crecimiento de neuritas | |
| RU2003100828A (ru) | Имидазопиридиновые и имидазопиримидиновые антивирусные агенты | |
| JP2004503501A5 (es) | ||
| AU728826B2 (en) | Compositions for treating and preventing arterial thrombosis and use of a factor Xa inhibitor on its own and/or combined with a platelet antiaggregating agent | |
| NO306295B1 (no) | Heterosykliske forbindelser, farmasöytiske preparater som omfatter slike forbindelser, samt anvendelse av forbindelsene til fremstilling av medikamenter | |
| HUT65890A (en) | Process for preparation of aromatic amidine derivatives and pharmaceutical compositions containing them | |
| DE68913930D1 (de) | Serotonin- und Norepinephrin-Aufnahme-Inhibitoren. | |
| UY23840A1 (es) | Procedimiento para la preparacion de inhibidores de la proteasa del vih | |
| BR0014526A (pt) | Compostos cìclicos de seis elementos contendo nitrogênio aromático | |
| RU2002111561A (ru) | 2'-замещенные 1,1'-бифенил-2-карбонамиды, способы их получения, их применение в качестве лекарственного средства, а также содержащие их фармацевтические композиции | |
| BR0010520A (pt) | Novos compostos farmaceuticamente ativos | |
| DK0759919T3 (da) | Azolidindioner som antihyperglykæmiske midler | |
| CA2107223A1 (en) | Crystalline tiagabine hydrochloride monohydrate, its preparation and use | |
| NO984740L (no) | Isatinderivater som acetylcholinesteraseinhibitorer og analgetiske midler | |
| AR007021A1 (es) | Derivados de 3-descladinosa-2,3-anhidroeritromicina, procedimientos para su preparacion, compuestos para su exclusivo uso en dichos procedimientosy procedimiento para su preparacion, una composicion farmaceutica para tratar infecciones bacterianas y el uso de estos compuestos para preparar medicamentos | |
| RU99101864A (ru) | Новое производное тиофена и содержащая его фармацевтическая композиция | |
| DK0429370T3 (da) | Hiditl ukendte thiophenderivater, fremgangsmåde til fremstilling heraf og farmaceutiske midler, som indeholder dem | |
| KR930017887A (ko) | 약제학적 화합물 | |
| IL91648A (en) | Amino acid quinoline and naphthyridine derivatives, their preparation and pharmaceutical compositions containing them | |
| KR100584032B1 (ko) | 항혈전제로서의 비스피페리딘 | |
| MY155914A (en) | Indolylpiperidine derivatives as antihistaminic and antiallergic agents | |
| NO20014127L (no) | 5-HT1F agonister |